Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell Lymphoma

Exclusion Criteria

• •History of allergic reactions attributed to any drug used in the study.
• •Any lymphoma-directed therapy within 4 weeks.
• •Any prior treatment with vincristine sulfate liposome injection.
• •Prior treatment with bendamustine or vincristine sulfate within 180 days of enrollment.
• •Patients who are receiving any other investigational agents with the exception of endocrine therapy for breast or prostate cancer.
• •Central nervous system involvement.
• •Peripheral sensory or motor neuropathy.
• •History of a demyelinating condition.
• •Positive test for the Human Anti-Chimeric Antibody (HACA).
• •Patients receiving any medications or substances that are strong inhibitors or inducers of Cytochrome P450, family 3, subfamily A (CYP3A) enzyme are ineligible.
• •Uncontrolled intercurrent illness.
• •Prisoners.
• •Pregnant or breast-feeding women.
• •Known Human Immunodeficiency Virus (HIV) or active Hepatitis B infection
• •Any prior or active cancer, which in the opinion of the investigator would preclude safe participation in this study.